Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. COVID public health emergency to stay in place

Published 11/11/2022, 03:34 PM
Updated 11/11/2022, 08:40 PM
© Reuters. FILE PHOTO: The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

By Ahmed Aboulenein and Jeff Mason

WASHINGTON (Reuters) -The United States will keep in place the public health emergency status of the COVID-19 pandemic, allowing millions of Americans to still receive free tests, vaccines and treatments, two Biden administration officials said on Friday.

The possibility of a winter surge in COVID cases and the need for more time to transition out of the public health emergency to a private market were two factors that contributed to the decision not to end the emergency status in January, one of the officials said.

The public health emergency was initially declared in January 2020, when the coronavirus pandemic began, and has been renewed each quarter since for 90 days. But the government in August began signaling it planned to let it expire in January.

The U.S. Department of Health and Human Services (HHS) has promised to give states 60 days' notice before letting the emergency expire, which would have been on Friday if it did not plan on renewing it again in January. The agency did not provide such notice, the second official said.

Health experts believe a surge in COVID-19 infections in the United States is likely this winter, one official said.

"We may be in the middle of one in January," he said. "That is not the moment you want to pull down the public health emergency."

Daily U.S. cases are down to an average of nearly 41,300 as of Nov. 9, but an average of 335 people a day are still dying from COVID, according to the latest U.S. Centers for Disease Control and Prevention data.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

Daily U.S. cases are projected to rise slowly to nearly 70,000 by February, driven by students returning to schools and cold weather-related indoor gatherings, the University of Washington's Institute for Health Metrics and Evaluation said in an Oct. 21 analysis. Deaths are forecast to remain at current levels.

The officials said a lot of work remained to be done for the transition out of the public health emergency.

The government has been paying for COVID vaccines, some tests, and certain treatments, as well as other care under the public health emergency (PHE) declaration. When the emergency expires, the government will begin to transfer COVID healthcare to private insurance and government health plans.

Health officials held large meetings with insurers and drugmakers about moving sales and distribution of COVID vaccines and treatments to the private sector in August and October, but none have been publicly announced since.

"The biggest motivation from a policy perspective is ensuring a smooth transition to the commercial market and the challenge of unraveling the multiple protections that have been put in place," said Dr. Jen Kates, senior vice president at the Kaiser Family Foundation. "Extending the PHE provides more time to manage that."

The biggest challenge is uninsured people, she said. Most Americans have government-backed or private health insurance and are expected to pay nothing for COVID vaccines and boosters, though they will likely incur some out-of-pocket costs for tests and treatments.

Uninsured children will also continue to get free vaccines, but it is unclear how they and some 25 million uninsured adults will avoid paying the full cost of tests and treatments, and how those adults will get vaccines.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

Their number is set to grow with the emergency expiring. HHS estimates that as many as 15 million people will lose health coverage after a requirement by Congress that state Medicaid programs keep people continuously enrolled expires and states return to normal patterns for enrollment.

Latest comments

No one wants to take a chance on being poisoned by mRNA vaccines it appears as boosters are going over like a lead balloon.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.